This is a preview of subscription content, log in via an institution to check access.
References
Saab S, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary Pharmacology and Therapeutics : 28 Jul 2014. Available from: URL: http://doi.org/10.1111/apt.12871.
Vellopoulou A, et al. Cost Utility of Telaprevir-PR (Peginterferon-Ribavirin) Versus Boceprevir-PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Applied Health Economics and Health Policy : 8 Aug 2014. Available from: URL: http://doi.org/10.1007/s40258-014-0120-y.
Dan YY, et al. Cost-effectiveness of boceprevir co-administration versus peginterferon alpha-2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore. Antiviral Therapy : 8 Aug 2014. Available from: URL: http://doi.org/10.3851/IMP2825.
Rights and permissions
About this article
Cite this article
Which hep C therapies fit the bill?. PharmacoEcon Outcomes News 710, 28 (2014). https://doi.org/10.1007/s40274-014-1501-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1501-z